Visby Medical, a company in the field of rapid at-home PCR diagnostics, has secured approximately $55m, with potential total funding reaching $65m, in its latest funding round.
The financing round was led by Catalio Capital Management.
Other participants in the round include previous investors such as ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, Pitango Ventures, and John Doerr.
The funding aims to advance the launch and distribution of Visby Medical’s US Food and Drug Administration (FDA)-authorised at-home Women’s Sexual Health Test, a sexually transmitted infections (STI) test.
Catalio Capital Management will support Visby Medical in expanding its market presence and operational capabilities.
Visby Medical founder and CEO Adam de la Zerda said: “We are excited to partner with Catalio Capital Management, a true industry powerhouse, as we advance our mission to transform healthcare through rapid and convenient at-home diagnostics that deliver the same accuracy as traditional PCR machines.
“This funding round will enable Visby to deliver on our vision of empowering consumers with reliable and lab-accurate health information from the comfort of their homes, starting with our at-home test for sexually transmitted infections for women.”
The at-home Women’s Sexual Health Test is claimed to be the first single-use PCR diagnostic that provides results within 30 minutes via a connected smartphone application.
Upon positive results, users can access telemedicine providers for consultation and treatment, promoting greater healthcare accessibility and privacy. The product will be accessible from July 2025 through major direct-to-consumer channels, said Visby Medical.
Catalio Capital Management partner Isaac Ro said: “Visby Medical has delivered the first and only laboratory-grade STI testing solution that can be made directly accessible to individuals.
“We were eager to invest in Visby ahead of their FDA clearance, knowing this would represent a breakthrough moment for the diagnostics industry. We are proud to support the company in its mission to reshape healthcare delivery.”
In related developments, Visby Medical recently submitted its Men’s Sexual Health Test to the FDA for 510(k) clearance and CLIA waiver. If approved, the test is expected to provide rapid PCR results in under 30 minutes for detecting Chlamydia and Gonorrhea from male urine samples in both symptomatic and asymptomatic men.
Visby Medical said that this single-use diagnostic requires no capital investment or refrigeration, making it suitable for various clinical environments like urgent care centers and physician offices. It utilises the same technology as the Visby Medical Women’s Sexual Health Test, which received over-the-counter approval earlier in March 2025.
